|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,838.30 INR | +0.74% |
|
+1.69% | +6.90% |
| 06-20 | Sun Pharma to acquire Innovcare Lifesciences for $28.7 million | RE |
| 06-10 | Organon wins US approval to widen use of arthritis biosimilar drug | RE |
| Market Cap | 4,411B 46.77B 40.77B 37.72B 35.35B 66.19B 66.71B 448B 173B 2,171B 176B 172B 7,545B | P/E 2026 |
36.8x | P/E 2027 * | 33.6x |
|---|---|---|---|---|---|
| Enterprise Value | 4,186B 44.39B 38.7B 35.8B 33.55B 62.83B 63.32B 425B 165B 2,061B 167B 163B 7,162B | EV / Sales 2026 |
6.72x | EV / Sales 2027 * | 6.34x |
| Free-Float |
44.39% | Yield 2026 |
0.91% | Yield 2027 * | 0.86% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.74% | ||
| 1 week | +1.69% | ||
| Current month | +2.17% | ||
| 1 month | -2.34% | ||
| 3 months | +5.38% | ||
| 6 months | +5.35% | ||
| Current year | +6.90% |
| 1 week | 1,792.6 |  | 1,842.7 |
| 1 month | 1,756.8 | | 1,903 |
| Current year | 1,583.7 | | 1,916.6 |
| 1 year | 1,548 | | 1,916.6 |
| 3 years | 977.3 | | 1,960.35 |
| 5 years | 661.5 | | 1,960.35 |
| 10 years | 312 | | 1,960.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 2025-08-31 | |
| Director of Finance/CFO | 58 | 2025-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 73 | 2018-05-24 | |
| Director/Board Member | 70 | 2021-05-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | +1.69% | +11.57% | +83.50% | 46.74B | |
| -2.91% | +3.09% | +49.98% | +91.04% | 34.33B | |
| -0.27% | -2.71% | -8.91% | +33.68% | 11.57B | |
| -0.34% | -3.07% | +12.71% | +93.23% | 11.42B | |
| -0.57% | +0.96% | +38.89% | +128.26% | 9.09B | |
| +0.43% | -1.68% | +14.22% | +40.48% | 6.98B | |
| -1.23% | +1.65% | +43.80% | -18.26% | 6.55B | |
| +2.77% | +1.83% | +35.04% | +245.66% | 6.62B | |
| +0.73% | -2.94% | -36.14% | -5.18% | 5B | |
| -0.27% | -2.10% | +20.41% | +107.94% | 4.06B | |
| Average | -0.09% | -0.13% | +18.16% | +80.03% | 14.24B | |
| Weighted average by Cap. | -0.43% | +0.91% | +22.28% | +83.23% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 583B 6.18B 5.38B 4.98B 4.67B 8.74B 8.81B 59.14B 22.91B 287B 23.18B 22.69B 997B | 654B 6.94B 6.05B 5.59B 5.24B 9.82B 9.9B 66.42B 25.74B 322B 26.04B 25.48B 1,119B |
| Net income | 116B 1.23B 1.07B 991M 929M 1.74B 1.75B 11.77B 4.56B 57.07B 4.61B 4.51B 198B | 133B 1.41B 1.23B 1.13B 1.06B 1.99B 2.01B 13.46B 5.22B 65.28B 5.28B 5.16B 227B |
| Net Debt | -224B -2.38B -2.07B -1.92B -1.8B -3.37B -3.39B -22.76B -8.82B -110B -8.92B -8.73B -384B | -264B -2.8B -2.44B -2.26B -2.11B -3.96B -3.99B -26.78B -10.38B -130B -10.5B -10.27B -451B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-19 | 1,838.30 ₹ | +0.74% | 2,126,703 |
| 26-06-18 | 1,824.80 ₹ | +0.24% | 2,054,738 |
| 26-06-17 | 1,820.40 ₹ | +1.09% | 1,771,990 |
| 26-06-16 | 1,800.70 ₹ | -0.29% | 1,373,638 |
| 26-06-15 | 1,806.00 ₹ | -0.09% | 2,188,933 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
